Are you a patient?
Please visit our patient website for more information on cataract treatment:
Interview with Dr. Durval - Cataract and Glaucoma surgeon and vice president of the Brazilian Cataract and Refractive Surgery Association - on the patients´ post-operative success stories and visual long-term performance of ZEISS AT LISA tri.
Having implanted 20,000 ZEISS AT LISA tri IOLs himself, Dr. Jørn S. Jørgensen, Chairman, CEO and Founder of EuroEyes International, shares his long-standing expertise on IOL surgery and patient consultation.
This peer-reviewed publication is the longest study, reviewing Long-Term Efficacy, Visual Performance and Patient Reported Outcomes with Trifocal Intraocular Lenses.
Let your patients learn at home
Enable your patients to safely inform themselves in the comfort of their own homes prior to the consultation in your clinic. ZEISS provides material that allow patients to get upfront information about cataracts, treatment options and the benefits of trifocal IOLs – in a comfortable, safe and efficient experience. Not only can patients educate themselves, but you’ll be able to reduce overall chair-time during future consultations.
Get your remote patient learning tools now.
Address patient needs and manage expectations
As a cataract expert, you know the best treatment option for every patient. Facilitate your personal patient consultation process by using ZEISS support material that help you understand the needs of your patients and manage their expectations even better. Patient-friendly tools help to better explain different treatment options and visualize the benefits of trifocal IOLs. And with a take-away brochure, patients have the possibility to review the information at home and gain reassurance regarding treatment with ZEISS AT LISA tri.
Get your face-to-face consultation tools now.
Attract patients to your clinic and promote benefits of premium IOL treatment
Reaching out to your patients with the right messaging requires time and resources. With our ZEISS AT LISA tri promotion tools for online, print and in-clinic communication, you can directly show the benefits of IOL treatments and attract patients to your clinic in an appealing and engaging way.
Get your direct promotion tools now.
AT LISA® tri family from ZEISS has repeatedly been the focus of scientific investigations when evaluating the performance of presbyopia-correcting IOLs. It has become the reference trifocal IOL, having been featured in numerous comparative analyses with other trifocal IOLs. Throughout these investigations, ZEISS AT LISA tri family has continually confirmed their excellent performance.
Outcomes from more than 4,500 patients implanted with ZEISS AT LISA tri family have already been analyzed in peer-reviewed articles. In evaluating these patient outcomes, surgeons have overwhelmingly discovered the same thing over and over again: high satisfaction and excellent visual outcomes. Thanks to this high predictability, you are able to constantly deliver optimal patient care.
Proven results and high patient satisfaction of the ZEISS AT LISA tri family are not confined to one region. Rather, outstanding results of peer-reviewed studies have been published by 60 different first authors from more than 20 countries. ZEISS AT LISA tri family prove to deliver high visual quality to patients worldwide, regardless of their origin.
Numerous peer-reviewed publications investigated patient-reported outcomes after ZEISS AT LISA tri IOL implantation. Repeatedly, surgeons confirmed high patient satisfaction, further proving the excellent performance of the reference trifocal technology.
A presbyopia-correcting IOL with excellent outcomes. The reference trifocal IOL AT LISA tri from ZEISS.
The first peer-reviewed publication on Long-Term Efficacy, Visual Performance and Patient Reported Outcomes with a Trifocal Intraocular Lens.
Explore the benefits and technical specifications of the ZEISS AT LISA tri family in more depth.